News

INmune Bio Inc. to Present at Key Healthcare Conference

INmune Bio Inc. to Present at Key Healthcare Conference

INmune Bio Inc. at the RBC Capital Markets Global Healthcare Conference

INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage biotechnology firm based in Boca Raton, Florida, is set to showcase its innovative research at the upcoming RBC Capital Markets Global Healthcare Conference. This noteworthy event will take place on May 20-21, where the company will reveal its cutting-edge advancements in the fields of inflammation and immunology.

Event Details

The RBC Capital Markets Global Healthcare Conference offers the ideal platform for INmune Bio to engage with investors and stakeholders. The event will follow a unique format, including a Fireside Chat and one-on-one virtual meetings. Attendees can find INmune Bio's presentation scheduled for 11:00 am EDT. Such conferences are crucial as they facilitate valuable connections and provide insights into the company's strategic direction and scientific breakthroughs.

About INmune Bio Inc.

Founded with the vision of transforming how diseases linked to the innate immune system are treated, INmune Bio is at the forefront of biotechnology innovation. The company has developed three primary product platforms that leverage dominant-negative technologies aimed at neutralizing key inflammatory factors.

The Dominant-Negative Platform

At the heart of INmune Bio’s offerings is the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform. This innovative technology focuses on selectively neutralizing soluble tumor necrosis factor, which is often a significant contributor to innate immune dysfunction and underlies many chronic diseases. Clinical trials involving DN-TNF candidates are currently investigating potential treatments for mild Alzheimer’s disease, mild cognitive impairment, and treatment-resistant depression, branded as XPro™.

Natural Killer Cell Priming

Additionally, the Natural Killer Cell Priming Platform is an exciting initiative that includes INKmune®. Designed to activate a patient’s natural killer (NK) cells, INKmune® aims to eradicate minimal residual disease in cancer patients. Current trials are examining its efficacy in treating metastatic castration-resistant prostate cancer, an area that desperately needs new therapeutic approaches.

Cord-Strom Cell Technology

Another promising avenue for INmune Bio is its proprietary CORDStrom™ program, which utilizes human umbilical cord-derived mesenchymal stem/stromal cells (hucMSCs). Recently, this program concluded a blinded randomized trial for recessive dystrophic epidermolysis bullosa, demonstrating the company’s commitment to addressing various medical challenges through advanced biotechnology.

Commitment to Innovation

As a publicly traded entity, INmune Bio Inc. is dedicated to pushing the boundaries of medical science. By focusing on a precision medicine approach, it addresses diseases that are largely driven by chronic inflammation and offers hope for better patient outcomes. Interested parties are encouraged to learn more about their pioneering work and product platforms by visiting their official website.

Frequently Asked Questions

What is the purpose of INmune Bio's presentation at the conference?

INmune Bio aims to showcase its innovations in biotechnology focused on inflammation and immunology, providing insights into their ongoing research and development.

When will the RBC Capital Markets Global Healthcare Conference occur?

The conference is scheduled for May 20-21, where INmune Bio will participate in key discussions and presentations relevant to their field.

What technologies does INmune Bio focus on?

INmune Bio focuses on several innovative platforms, including DN-TNF for inflammatory diseases, NK cell priming for cancer, and CORDStrom™ for regenerative medicine.

How can I learn more about INmune Bio?

You can explore more about INmune Bio and their product platforms by visiting their website at www.inmunebio.com.

What is the significance of the company's research?

INmune Bio's research is crucial as it explores novel therapies for conditions usually linked with chronic inflammation, providing potential new solutions for complex diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Radiation Oncology Text Earns Doody's 2026 Nod

Updated Category News Views 24

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Continue Reading
Curis Prepares for Q3 2026 Results Amid Tough Sector Trends

Updated Category News Views 139

All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...

Continue Reading
Home Insurance Depreciation and What it Means for You

Updated Category News Views 17

A Deep Dive into Depreciation's Impact on Home Insurance Folks, if you haven't battled the insurance beast, you're missing out on an unholy mess. Let's talk about something that's been quietly gnawing at homeowners’ wallets—depreciation in home insurance claims. Peggy Schneider, an insurance guru from Kalispell, Montana, lays it all out in HelloNation, and I'm here to...

Continue Reading
FDA Greenlights Halozyme's Cancer Treatment Breakthrough

Updated Category News Views 18

FDA's Seal of Approval: A Game Changer Well, folks, here's a twist in the story of cancer treatment with FDA giving a nod to RYBREVANT FASPRO. Johnson & Johnson's latest offering, fueled by Halozyme's groundbreaking ENHANZE technology, just snagged accelerated approval. We're not just talking any old treatment here; it's a dual-targeted therapy for head and neck cancer...

Continue Reading
Birth Registration Revolution: OSIA Interoperability Demo

Updated Category News Views 86

Bringing Birth Registration into the 21st Century Alright, let's cut through the fog. If you ask most folks about their birth certificates, you'd hear tales of tattered paper and government office runs. What if I told you this vital piece of paper could be reborn altogether? That's what the Secure Identity Alliance is up to with their OSIA Live Interoperability Demo at...

Continue Reading
TELUS Boosts Board with Strategic Executive Appointments

Updated Category News Views 47

New Faces on the TELUS Board: Shaping the Future Alright, investors, here's the scoop straight from the trenches: TELUS (TSX:TU) is shaking things up at the top. Marc Allera and Bill Thomas are stepping into the fray as the newest members of the board, effective January 1, 2027. If you're not familiar with these names, it's time to tune in because they've got the chops to...

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 68

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Bowling Makes a Strike at Macy's 100th Parade in NYC

Updated Category News Views 64

Rolling with Tradition: Bowling at Macy's Parade Back in the day, bowling wasn't exactly the sport making headlines. But times, they change. Here we are in the thick of things, witnessing Go Bowling getting its moment in the spotlight during the historic 100th Macy's Thanksgiving Day Parade®. It's not about raking in the dough or hitting some stocks; it’s about...

Continue Reading
PPL Reports Strong Q3; Long-Term EPS Growth Up

Updated Category News Views 29

Solid Earnings in a Challenging Market Anytime you start hearing a company like PPL boasting about their quarterly earnings, it's time to sit up straight and pay attention. The utility giant didn’t just match expectations, they beat 'em, clocking in with $0.54 per share in ongoing earnings for Q3 2026, up from $0.48 the previous year. Not a bad step forward if you ask...

Continue Reading
Tucows Shows Progress in Q3 2026 Amidst Net Loss

Updated Category News Views 140

Q3 Snapshot: Balancing Act at Tucows Man, if there's one thing you can count on from Tucows, it's that they'll shuffle the deck just when you're getting comfortable. Here in the third quarter of 2026, they've managed a decent juggling act. Their unaudited numbers show consolidated net revenue ticking up 1.4% from last year, rounding out at a cool $100 million. That's...

Continue Reading

Top 5 Most Recently Viewed Articles

Nicole Kidman's New Role as Clé de Peau Beauté Ambassador

Updated Category News Views 302

Nicole Kidman Joins Clé de Peau Beauté as Global Brand Ambassador The renowned and celebrated Hollywood actress, Nicole Kidman, has taken on a monumental role as the new Global Brand Ambassador for Clé de Peau Beauté, a brand recognized for its luxurious skincare and makeup offerings. Kidman's exceptional presence in the entertainment industry transcends mere stardom;...

Continue Reading
Future FinTech Group Unveils Innovative AI Trading Platform

Updated Category News Views 171

Future FinTech Group Launches AI-Powered Trading Platform Future FinTech Group Inc. (NASDAQ: FTFT), known for its comprehensive financial and digital technology services, has initiated an exciting endeavor with its subsidiary, FTFT International Securities & Futures Co., Ltd. ("Future Securities"). This strategic move aims to revolutionize investment analytics and trading...

Continue Reading
GardaWorld Finalizes Successful Credit Facility Enhancements

Updated Category News Views 124

GardaWorld's Strategic Credit Facility Enhancements MONTREAL / -- Garda World Security Corporation, known as GardaWorld, is making significant strides in its operational efficiency and financial management. This entrepreneurial-driven company specializes in security services and innovative risk solutions. Recently, GardaWorld has successfully completed amendments to its...

Continue Reading
Transformative Trends in eCommerce: The Future of Marketing

Updated Category News Views 361

Understanding the Future of eCommerce Marketing As we approach a pivotal moment in the eCommerce realm, it's essential to recognize the trends that are not only shaping the industry today but are also setting the stage for 2025. The digital marketplace is evolving rapidly, and organizations must adapt to thrive. Based on insights shared by leading experts, including CEO...

Continue Reading
OSE Immunotherapeutics Reveals Strategic Innovations for Growth

Updated Category News Views 238

OSE Immunotherapeutics Shapes Future with 2026-2028 Strategic Vision OSE Immunotherapeutics has unveiled an ambitious strategic plan aimed at enhancing its product offerings and maximizing shareholder value. This plan is designed for the upcoming three years and spans innovative treatments and strategic initiatives that promise to propel the company forward in the...

Continue Reading